ClinicalTrials.gg
Active, not recruitingNCT03924895Updated Jun 30, 2026Results posted

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

A Phase 3 interventional study of Pembrolizumab and Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]) in Urinary Bladder Cancer, Muscle-invasive, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 242 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
595
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing pembrolizumab in Urinary Bladder Neoplasms — 13 open to participants now, 20 under way, 5 of them phase 3. pembrolizumab · Urinary Bladder Neoplasms.

Enrollment
3rd of 39
595 · median 60
Started
2019
with 3 others
Phase 3
8 of 39
2 open now
Primary completion
2025-06
later than 2 of 19 live
Registered
19th of 39
by date
Lead sponsor
7 of 39
Merck Sharp & Dohme LLC

Among the 39 studies testing pembrolizumab in Urinary Bladder Neoplasms, this one is the 3rd largest by enrollment, is one of 4 that started in 2019, is one of 8 in phase 3, reaches primary completion later than 2 of the 19 other live ones, and was the 19th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

13 of the 39 studies testing pembrolizumab in Urinary Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing pembrolizumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC).

The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plus pelvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination with pembrolizumab plus RC+PLND will achieve superior event-free survival (EFS) compared with RC+PLND alone.

With Amendment 5, outcome measures for programmed cell death ligand 1 (PD-L1) combined positive score (CPS) were removed.

With Amendment 8, the primary outcome measure of pathologic complete response (pCR) rates was changed to a secondary outcome measure.

03

Conditions studied

  • Urinary Bladder Cancer, Muscle-invasive

Keywords

  • Muscle-Invasive Bladder Cancer (MIBC)
  • Enfortumab vedotin (EV)
  • Pembrolizumab (MK-3475)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed diagnosis of urothelial carcinoma/muscle-invasive bladder cancer [MIBC] (cT2-T4aN0M0 or T1-T4aN1M0) with predominant (≥50%) urothelial histology to be confirmed by Blinded Independent Central Review (BICR) (central pathology and/or imaging).
  • Clinically nonmetastatic bladder cancer determined by imaging
  • Eligible for radical cystectomy (RC) + pelvic lymph node dissection (PLND), and agreement to undergo curative intent standard RC + PLND (including prostatectomy if applicable)
  • Ineligible for treatment with cisplatin, as defined by meeting at least one of the following criteria OR be eligible for treatment with cisplatin but decline treatment with cisplatin-based chemotherapy:

    • Impaired renal function with measured or calculated (CrCl) 30 to 59 mL/min (calculated by Cockcroft-Gault method, Modification of Diet of Renal Disease [] equations, or measured by 24-hour urine collection)
    • (ECOG) Performance Status 2
    • (CTCAE) v.4 Grade ≥2 audiometric hearing loss
    • (NYHA) Class III heart failure
  • Transurethral resection (TUR) of a bladder tumor that is submitted for central pathology assessment and adequate to determine urothelial histology and expression assessment
  • ECOG performance status of 0, 1, or 2
  • Adequate organ function
  • A male participant is eligible to participate if he agrees to use and refrain from donating sperm during the intervention period and for at least 180 days after the last dose of enfortumab vedotin. If the male participants are receiving pembrolizumab only or undergoing surgery only, there are no contraception requirements
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a (woman of ) WOCBP or a WOCBP who agrees to use a highly effective contraceptive method or be abstinent from heterosexual intercourse (as their preferred and usual lifestyle) during the intervention period and for at least 120 days after the last dose of pembrolizumab and at least 180 days after the last dose of enfortumab vedotin; whichever comes last. A female participant must agree not to donate eggs during this period as well
  • A WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • Known additional nonurothelial that is progressing or has required active anticancer treatment ≤3 years of study randomization, with certain exceptions
  • Has ≥ N2 or disease (M1) as identified by imaging
  • Received any prior systemic treatment, chemoradiation, and/or radiation therapy for muscle-invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC)
  • Received prior therapy with an anti-programmed cell death protein 1 (), anti-programmed death-ligand 1 (PD-L1), or anti-programmed cell death 1 ligand 2 (PD-L2), or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Received prior systemic anticancer therapy including agents within 3 years prior to randomization
  • Received any prior radiotherapy to the bladder
  • Received a partial cystectomy of the bladder to remove any non-muscle-invasive bladder cancer (NMIBC) or MIBC
  • Received a live or within 30 days before the first dose of study intervention
  • Current participation in or participation in a study of an investigational agent or use of an investigational device within 4 weeks prior to the first dose of study intervention
  • Ongoing sensory or motor neuropathy Grade 2 or higher
  • Diagnosis of immunodeficiency or receipt of chronic systemic therapy or any other form of therapy within 7 days prior the first dose of study drug. Physiologic replacement doses of corticosteroids are permitted for participants with adrenal insufficiency.
  • to monoclonal antibodies (including pembrolizumab) and/or any of their
  • Severe hypersensitivity (≥ Grade 3) to enfortumab vedotin or any excipient contained in the drug formulation of enfortumab vedotin
  • Active keratitis or corneal ulcerations. Participants with superficial punctate keratitis are allowed if the disorder is being adequately treated in the opinion of the investigator
  • Active disease that has required systemic therapy in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic therapy and is allowed
  • Has uncontrolled diabetes
  • History of (noninfectious) pneumonitis that required steroids, or current pneumonitis
  • Active infection requiring systemic therapy
  • Has had an allogeneic tissue/solid organ transplant
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
595 participants (actual)

Study arms

  • Experimental
    Arm A: Pembrolizumab + Surgery

    Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.

    Drug: Pembrolizumab · Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])

  • Active comparator
    Arm B: Surgery alone

    Participants receive standard of care surgery alone.

    Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])

  • Experimental
    Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery

    Participants receive 3 preoperative cycles of enfortumab vedotin + pembrolizumab, followed by standard of care surgery, followed by 6 cycles of postoperative enfortumab vedotin + pembrolizumab, followed by 8 cycles of pembrolizumab alone. Each cycle is 21 days.

    Drug: Enfortumab Vedotin

Interventions

  • Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

    Also known as: KEYTRUDA®, MK-3475

  • ProcedureSurgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])

    Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.

  • Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.

    Also known as: Padcev, ASG-22CE, ASG-22ME

06

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone

    EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes radical cystectomy + pelvic lymph node dissection (RC + PLND) surgery, failure to undergo RC + PLND surgery in participants with residual disease and any radiographic disease present (biopsy-proven muscle-invasive bladder cancer \[MIBC\] will be considered an event regardless of radiographic findings), gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy, or death due to any cause.

    Time frame: Up to approximately 53 months

Secondary outcomes

  1. EFS Between Arm A and Arm B

    EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery or failure to undergo RC surgery in participants with residual disease (biopsy-proven muscle-invasive bladder cancer \[MIBC\] will be considered an event regardless of radiographic findings), gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy, or death due to any cause.

    Time frame: Up to approximately 6.75 years

  2. Overall Survival (OS) Between Arm C and Arm B

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 7.6 years

  3. OS Between Arm A and Arm B

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 7.6 years

  4. Pathologic Complete Response (pCR) Rate Between Arm C and Arm B

    Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as assessed by blind independent central review (BICR).

    Time frame: Up to approximately 53 monhts

  5. pCR Rate Between Arm A and Arm B

    Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as determined centrally.

    Time frame: Up to approximately 5.7 years

  6. Disease-Free Survival (DFS)

    DFS is defined as the time from first post-surgery baseline scan until: * local or distant recurrence as assessed by imaging and/or biopsy * Death due to any cause

    Time frame: Up to approximately 6.75 years

  7. Pathologic Downstaging (pDS) Rate Between Arm A and Arm B

    Pathologic downstaging rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of \<pT2 (includes pT0, pTis, pTa, pT1) and N0 in examined tissue from RC and PLND.

    Time frame: Up to approximately 5.7 years

  8. Pathologic Downstaging {pDS) Rate Between Arm C and Arm B

    Pathologic downstaging (pDS) is defined as participants with a tumor classification of \<pT2. The pathologic stage \<pT2 includes pT0 (No residual primary tumor found in the tissue examined), pTis (carcinoma in situ; a flat, non-invasive cancer confined to the epithelial lining), pTa (Non-invasive papillary carcinoma limited to the urothelium) pT1 (tumor has invaded the connective tissue beneath the urothelium, but not the muscle layer) and N0 (No cancer found in the examined lymph nodes) in examined tissue from RC and PLND. The \<pT2 category represents a better outcome than participants with residual muscle-invasive disease (pT2 or higher) and/or any nodal involvement (N1/N2). The percentage of participants with pDS is presented.

    Time frame: Up to approximately 53 months

  9. Number of Participants Experiencing Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.

    Time frame: Up to approximately 7.6 years

  10. Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.

    Time frame: Up to approximately 1 year

  11. Number of Participants Experiencing Perioperative Complications

    The number of participants who experience perioperative complications will be presented.

    Time frame: Up to approximately 1 year

07

Results

Posted Jun 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin (EV) + Pembrolizumab + Surgery
Started166259170
Treated166236170
Completed000
Not completed166259170
Withdrew: Death7410837
Withdrew: Withdrawal by subject383
Withdrew: Ongoing89143130

Outcome measures

PrimaryEvent-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone

EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes radical cystectomy + pelvic lymph node dissection (RC + PLND) surgery, failure to undergo RC + PLND surgery in participants with residual disease and any radiographic disease present (biopsy-proven muscle-invasive bladder cancer \[MIBC\] will be considered an event regardless of radiographic findings), gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy, or death due to any cause.

Time frame:
Up to approximately 53 months
Reported as:
Median · Months
Event-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone
MonthsArm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin + Pembrolizumab + Surgery
Event-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone—15.7 (10.3 to 20.5)NA (37.3 to NA)
Statistical analysis
  • Arm B: Surgery Alone vs Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by cisplatin status (cisplatin-ineligible vs cisplatin eligible but declined), tumor stage (T2N0 vs T3/T4aN0 vs T1-4aN1), and geographic regions (US vs EU vs MOW) with small strata collapsed) · Hazard ratio (hr): 0.40 · 95% CI 0.28 to 0.57
SecondaryEFS Between Arm A and Arm B

EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery or failure to undergo RC surgery in participants with residual disease (biopsy-proven muscle-invasive bladder cancer \[MIBC\] will be considered an event regardless of radiographic findings), gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy, or death due to any cause.

Time frame:
Up to approximately 6.75 years

Results for this outcome have not been posted.

SecondaryOverall Survival (OS) Between Arm C and Arm B

OS is defined as the time from randomization to death due to any cause.

Time frame:
Up to approximately 7.6 years

Results for this outcome have not been posted.

SecondaryOS Between Arm A and Arm B

OS is defined as the time from randomization to death due to any cause.

Time frame:
Up to approximately 7.6 years

Results for this outcome have not been posted.

SecondaryPathologic Complete Response (pCR) Rate Between Arm C and Arm B

Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as assessed by blind independent central review (BICR).

Time frame:
Up to approximately 53 monhts
Reported as:
Number · Percentage of Participants
Pathologic Complete Response (pCR) Rate Between Arm C and Arm B
Percentage of ParticipantsArm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin + Pembrolizumab + Surgery
Pathologic Complete Response (pCR) Rate Between Arm C and Arm B—8.6 (4.9 to 13.8)57.1 (49.3 to 64.6)
Statistical analysis
  • Arm B: Surgery Alone vs Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery · Miettinen & Nurminen method · p = <0.000001 · Difference in percentage: 48.3 · 95% CI 39.5 to 56.5Arm C: EV+ Pembrolizumab +Surgery vs Arm B: Surgery Alone
SecondarypCR Rate Between Arm A and Arm B

Pathologic complete response rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as determined centrally.

Time frame:
Up to approximately 5.7 years

Results for this outcome have not been posted.

SecondaryDisease-Free Survival (DFS)

DFS is defined as the time from first post-surgery baseline scan until: * local or distant recurrence as assessed by imaging and/or biopsy * Death due to any cause

Time frame:
Up to approximately 6.75 years

Results for this outcome have not been posted.

SecondaryPathologic Downstaging (pDS) Rate Between Arm A and Arm B

Pathologic downstaging rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of \<pT2 (includes pT0, pTis, pTa, pT1) and N0 in examined tissue from RC and PLND.

Time frame:
Up to approximately 5.7 years

Results for this outcome have not been posted.

SecondaryPathologic Downstaging {pDS) Rate Between Arm C and Arm B

Pathologic downstaging (pDS) is defined as participants with a tumor classification of \<pT2. The pathologic stage \<pT2 includes pT0 (No residual primary tumor found in the tissue examined), pTis (carcinoma in situ; a flat, non-invasive cancer confined to the epithelial lining), pTa (Non-invasive papillary carcinoma limited to the urothelium) pT1 (tumor has invaded the connective tissue beneath the urothelium, but not the muscle layer) and N0 (No cancer found in the examined lymph nodes) in examined tissue from RC and PLND. The \<pT2 category represents a better outcome than participants with residual muscle-invasive disease (pT2 or higher) and/or any nodal involvement (N1/N2). The percentage of participants with pDS is presented.

Time frame:
Up to approximately 53 months
Reported as:
Number · Percentage of Participants
Pathologic Downstaging {pDS) Rate Between Arm C and Arm B
Percentage of ParticipantsArm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin + Pembrolizumab + Surgery
Pathologic Downstaging {pDS) Rate Between Arm C and Arm B—12.6 (8.1 to 18.5)65.9 (58.2 to 73.0)
Statistical analysis
  • Arm B: Surgery Alone vs Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery · Miettinen & Nurminen Method · p = <0.000001 (p-value is nominal) · Difference in percentage: 53.1 · 95% CI 44.0 to 61.2Arm C: EV+ Pembrolizumab +Surgery vs Arm B: Surgery Alone
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.

Time frame:
Up to approximately 7.6 years

Results for this outcome have not been posted.

SecondaryNumber of Participants Discontinuing Study Drug Due to Adverse Events (AEs)

An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.

Time frame:
Up to approximately 1 year

Results for this outcome have not been posted.

SecondaryNumber of Participants Experiencing Perioperative Complications

The number of participants who experience perioperative complications will be presented.

Time frame:
Up to approximately 1 year

Results for this outcome have not been posted.

Adverse events

Collected over Up to approximately 69 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Pembrolizumab + Surgery76/166 (45.8%)107/163 (65.6%)143/163 (87.7%)
Arm B: Surgery Alone111/259 (42.9%)94/242 (38.8%)94/242 (38.8%)
Arm C: EV + Pembrolizumab + Surgery38/170 (22.4%)97/167 (58.1%)163/167 (97.6%)
Most frequent serious events
Showing 10 of 213
Most frequent serious events
EventArm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: EV + Pembrolizumab + Surgery
Urinary tract infectionInfections and infestations15/16317/24217/167
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)13/16311/2423/167
Acute kidney injuryRenal and urinary disorders5/1633/2428/167
PyelonephritisInfections and infestations7/1632/2426/167
SepsisInfections and infestations7/1637/2425/167
UrosepsisInfections and infestations3/1638/2427/167
PneumoniaInfections and infestations5/1632/2425/167
HydronephrosisRenal and urinary disorders5/1633/2421/167
Intestinal obstructionGastrointestinal disorders4/1632/2424/167
Postoperative wound infectionInfections and infestations4/1631/2421/167
Most frequent other events
Showing 10 of 48
Most frequent other events
EventArm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: EV + Pembrolizumab + Surgery
PruritusSkin and subcutaneous tissue disorders28/1631/24278/167
AlopeciaSkin and subcutaneous tissue disorders1/1630/24258/167
DiarrhoeaGastrointestinal disorders23/1637/24254/167
FatigueGeneral disorders26/16312/24254/167
AnaemiaBlood and lymphatic system disorders49/16327/24251/167
Decreased appetiteMetabolism and nutrition disorders23/1639/24247/167
DysgeusiaNervous system disorders5/1630/24247/167
ConstipationGastrointestinal disorders23/16318/24244/167
NauseaGastrointestinal disorders21/16316/24243/167
RashSkin and subcutaneous tissue disorders16/1632/24241/167

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin (EV) + Pembrolizumab + SurgeryTotal
Mean71.8 ± 7.971.9 ± 7.772.1 ± 7.971.9 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin (EV) + Pembrolizumab + SurgeryTotal
Female366633135
Male130193137460
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin (EV) + Pembrolizumab + SurgeryTotal
Hispanic or Latino315826
Not Hispanic or Latino155231160546
Unknown or Not Reported813223
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin (EV) + Pembrolizumab + SurgeryTotal
American Indian or Alaska Native0101
Asian16383185
Native Hawaiian or Other Pacific Islander0000
Black or African American1427
White148205132485
More than one race07411
Unknown or Not Reported1416
Cisplatin Status
Cisplatin Status(Participants)Arm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin (EV) + Pembrolizumab + SurgeryTotal
Cisplatin-Ineligible163223142528
Cisplatin-Eligible but Declined3362867
Tumor Clinical Stage
Tumor Clinical Stage(Participants)Arm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin (EV) + Pembrolizumab + SurgeryTotal
T2N012403082
T3/T4aN0150209133492
T1-4aN1410721
Geographic Region
Geographic Region(Participants)Arm A: Pembrolizumab + SurgeryArm B: Surgery AloneArm C: Enfortumab Vedotin (EV) + Pembrolizumab + SurgeryTotal
United States (US)19332173
European Union (EU)7311078261
Most of World (MOW)7411671261
08

Study locations

242 sites

Showing the first 100 of 242 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, Goger YE, Rausch S, Kang SH, Loriot Y, Bedke J, Galsky MD, O'Donnell PH, von Amsberg G, Alimohamed N, Sulimka G, Gupta S, Paramonov V, Nakane K, Mihm M, Meng C, Huang CD, Ramamurthy C, Homet Moreno B, Ullen A; KEYNOTE-905/EV-303 Investigators. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026 Apr 2;394(13):1257-1269. doi: 10.1056/NEJMoa2511674. Epub 2026 Feb 18. PubMed 41707170 ↗
  • Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19. PubMed 34008425 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jun 2025, 70 months.

Results were first posted in Jun 2026, 1 year after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 70 months is above that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2019
First posted
Apr 23, 2019
StartActual
Jul 24, 2019
Primary completionActual
Jun 6, 2025
CompletionEst.
Dec 15, 2027
Results first posted
Jun 30, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03924895
Responsible party
Sponsor
First posted
Apr 23, 2019
Start date
Jul 24, 2019
Primary completion
Jun 6, 2025
Completion
Dec 15, 2027 (estimated)
Results posted
Jun 30, 2026
Last update
Jun 30, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Enfortumab vedotin

Start the discussion